Amifostine in clinical oncology: Current use and future applications

Anti-Cancer Drugs

Volumn 13, Issue 3, 2002, Pages 181-209

  Koukourakis, M I ^a  

^a Tumor and Angiogenesis Research Group Alexandroupolis   (Greece)

Author keywords

Amifostine; Chemotherapy; Cytoprotection; Radiation therapy

Indexed keywords

2 (3 AMINOPROPYLAMINO)ETHANETHIOL; ALKALINE PHOSPHATASE; AMIFOSTINE; BIS[2 (3 AMINOPROPYLAMINO)ETHYL] DISULFIDE; BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; IDARUBICIN; IFOSFAMIDE; MAFOSFAMIDE; MELPHALAN; MISONIDAZOLE; MITOMYCIN C; MITOXANTRONE; NAVELBINE; PACLITAXEL; PHOSPHOROTHIOIC ACID; PRODRUG; SCAVENGER; THIOL; VINBLASTINE; VINCRISTINE;

ACIDITY; ANIMAL EXPERIMENT; ANIMAL MODEL; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL HYPOXIA; CELL PROTECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPHOSPHORYLATION; DRUG EFFICACY; ENDOTHELIUM; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; HUMAN; IONIZING RADIATION; MOUSE; MUCOSA INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; RAT; REVIEW; STROMA; XEROSTOMIA;

AMIFOSTINE; ANIMALS; HUMANS; NEOPLASMS; RADIATION-PROTECTIVE AGENTS;

EID: 0036245127     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200203000-00001     Document Type: Review

References (208)

1. Studies on the mechanism of 5-hydroxytryptamine in radioprotection of mammals
2. Direct observation of a free radical interaction between vitamine E and vitamine C
3. Intraperitoneal cis-diaminochloroplatinum with systemic thiosulfate protection
4. Modification of cisplatin toxicity with diethyldithio carbamate
5. Cyclophosphamide cystitis: Identification of acrolein as the causative agent
6. High dose leucovorin as sole therapy for methotrexate toxicity
7. Colony stimulating factors in patients with fever and neutropenia
8. Erythropoietin for patients undergoing radiotherapy: A pilot study
9. A pilot study of the effect of granulocyte-macrophage colony stimulating factor on oral mucositis in head and neck cancer patients during X-radiation therapy: A preliminary report
10. Oral administration of recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) in the management of radiotherapy induced esophagitis
11. Cysteine protection against irradiation
12. Radiation protectors: The unexpected benefits
13. Biological characteristics of some improved radioprotectors
14. Chemoprotection against three models of radiation death in the mouse
15. The effect of S-2-(3-aminopropylamino) ethylphosphorothioic acid (WR-2721) on intestinal crypt survival. I. 4MeV X-rays
16. Protection of acute and late radiation damage of the gastrointestinal tract by WR-2721
17. Protective effects of S-2-(3-aminopropylamino)ethyl and phosphorothioic acid against radiation damage of normal tissues and a fibrosarcoma in mice
18. 2 or WR-2721 (WR-1065) protects mice from alopecia after fractionated irradiation
19. Radioprotection by WR-2721 against long term chronic damage to the rat parotid gland
20. Sparing of radiation-induced damage to the physis: Fractionation alone compared to amifostine pretreatment
21. Protection of mice against fission neutron irradiation by WR-2721 or WR-151327
22. A comparison of radioprotection from three neutron sources and Co-60, of WR-2721 and WR-151327
23. Amifostine: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential as a radioprotector and cytotoxic chemoprotector
24. The radioprotector WR-1065 reduces radiation-induced mutations at the hypoxanthine-guanine phosphoribosyl transferase locus in V79 cells
25. Radioprotectors in treatment therapy to reduce risk of secondary tumor induction
26. Protective effects of 2-[(aminopropyl)amino]ethanethiol against bleomycine and nitrogen mustard-induced mutagenicity in V79 cells
27. Protection against cis-diaminodichloroplatinum cytotoxicity and mutagenicity in V79 cells by 2-[(aminopropyl)amino]ethanethiol
28. 60Co-gamma ray irradiation
29. Modifiers of free radicals inhibit in vitro the oncogenic actions of X-rays, bleomycin and the tumor promotor 12-O-tetradecanoylphorbol-13-acetate
30. Inhibition of radiation carcinogenesis in mice by S-2-(3-aminopropylamino)-ethylphosphorothioic acid
31. The protective effect of cysteine on leukopenia induced by nitrogen mustard
32. Differential protection of normal and malignant tissue against the cytotoxic effects of mechlorethamine
33. Selective inhibition of nephrotoxicity of cis-platinum without altering its antitumor effectiveness
34. Modulation of cis-platinum renal toxicity by the radioprotective agent WR-2721
35. Modification of cyclophosphamide-induced pulmonary toxicity in normal mice
36. Cardioprotection of rat myocytes with amifostine (Ethyol®) and its free thiol, WR-1065, in vitro
37. Stimulation of haematopoiesis by amifostine in patients with myelodysplastic syndrome
38. Haematopoietic stimulation by amifostine and sodium phenylbutyrate: What is the potential in MDS?
39. + cells and promotes progenitor growth via polyamine-like effects
40. Poor response rate to a continuous schedule of amifostine therapy for low/intermediate risk myelodysplastic patients
41. Hydrolysis of WR-2721 by mouse liver cell fractions
42. Dephosphorylation of WR-2721 with mouse tissue homogenates
43. Metabolic pathways of WR-2721 (Ethyol, amifostine) in BALB/c mouse
44. A liquid chromatographic electrochemical assay for S-2-(3-aminopropylamino)ethylphosphorythiate (WR-2721) in human plasma
45. Localized areas of high alkaline phosphatase activity in endothelium of arteries
46. Alkaline phosphatase promotes radioprotection and accumulation of WR-1065 in V79-171 cells incubated in medium containing WR-2721
47. Sequence and characterization of human intestinal alkaline phosphatase gene
48. Human pharmacokinetics of WR-2721
49. Pharmacokinetics of WR-2721
50. Pharmacokinetics of amifostine: Effects of dose and method of administration
51. Specific protection of different normal tissues
52. A phase I study comparing bioavailability of intravenous and subcutaneous administration of amifostine (Ethyol)
53. Extended window of mucosal radioprotection with intravenous or subcutaneous amifostine in rats
54. Cytoprotective agents for anthracyclines
55. The effect of 2-[(aminoprolylamino]ethanthiol (WR-1065) in radiation induced double strand damage and repair in V79 cells
56. Variation in normal and tumor tissue sensitivity of mice to ionizing radiation-induced DNA strand breaks in vivo
57. Influence of WR-2721 on DNA-cross linking by nitrogen mustard in normal mouse bone marrow and leukemia cells in vivo
58. Effects of modulating agent WR-2721 and its main metabolites on the formation and stability of cisplatin-DNA adducts in vitro in comparison to the effects of thiosulphate and diethyldithiocarbamate
59. N-(2-mercaptoethyl)-1,3-propanediamine (WR-1065) protects thymocytes from programmed cell death
60. Enhancement of toposiomerase I-mediated unwinding of supercoiled DNA by the radioprotector WR-33278
61. 11(dithiodi-2,1-ethanediyl) bis1,3-propanediamine (WR-33278)
62. Interaction of cultured mammalian cells with WR-2721 and its thiol, WR-1065: Implications for mechanisms of radio; protection
63. Alterations in oxygen transport following WR-2721
64. The molecular basis of hypoxia response pathway: Tumour hypoxia as a therapy target
65. Has the outlook improved for amifostine as a clinical radioprotector?
66. Differential cytoprotection of normal and malignant tissues
67. 35S-labeled WR-2721 in normal and malignant tissues of the mouse
68. Active versus passive absorption kinetics as the basis for selective protection of normal tissue by S-2-(3-aminopropylamino)-ethylphosphorothioic acid
69. 35S-labeled 3-amino-2-hydroxypropyl phosphorothioate (WR-77913)
70. Radioprotection combined with hypoxic sensitization during radiotherapy of a solid murine tumor
71. Influence of WR-2721 on radiation response of canine soft tissue sarcomas
72. Improvement in radiotherapy for a murine sarcoma by indomethacin plus WR-2721
73. Treatment of tumours with the combination of WR-2721 and cis-dichlorodiammine-platinum (II) or cyclophosphamide
74. Dose and interval relationship for the interaction of WR-2721 and mustard with normal and malignant cells
75. Amifostine improves the antileukemic therapeutic index of mafosfamide: Implications for bone marrow purging
76. Effects of the modulating agent WR-2721 on myelotoxicity and antitumour activity in carboplatin-treated mice
77. Effect of WR-2721 on the toxicity and antitumor activity of the combination of carboplatin and 5-fluorouracil
78. Effects of amifostine and paclitaxel on growth of human ovarian carcinoma xenografts in the severe combined immune-deficient mouse: Preliminary results
79. Effects of amifostine (WR-2721, ethyol) on tumor growth and pharmacology of cytotoxic drugs in human xenotransplanted neuroblastomas
80. Amifostine does not alter the antitumor activity of cisplatin in a pre-clinical model of testicular cancer
81. Effects of amifostine on cisplatin induced DNA adduct formation and toxicity in malignant glioma and normal tissues in rat
82. Tumor sensitization and protection: Influence of stromal injury on estimates of dose modification
83. Fractionation studies with WR-2721: Normal tissues and tumour
84. Effect of radioprotective drugs on the therapeutic ratio for a mouse tumor system
85. Influence of WR 2721 on the efficacy of radiotherapy and chemotherapy of murine tumors
86. Effect of the radioprotective drugs MEA, DMSO, and WR-2721 on tumor control and skin tolerance in the rat
87. Effect of the radioprotector WR 2721 on the response of metastatic Lewis lung carcinoma colonies to alkylating agents
88. Radioprotection of mouse skin vasculature and the RIF-1 fibrosarcoma by WR-2721
89. Amifostine: The preclinical basis for broad spectrum selective cytoprotection of normal tissues from cytotoxic therapies
90. Amifostine: Mechanisms of action
91. Radioprotection of cultured Chinese hamster ovary cells by WR-255591
92. WR-1065, the active metabolite of amifostine (Ethyol), does not inhibit the cytotoxic effects of a broad range of standard anticancer drugs against human ovarian and breast cancer cells
93. The effects of amifostine on the in vitro cytotoxicity of chemotherapeutic agents in three epithelial ovarian carcinoma cell lines
94. Cytoprotection by WR-1065, the active form of amifostine, is independent of p53 status in human malignant glioma cell lines
95. Use of radiation with or without WR-2721 in advanced rectal cancer
96. Interim analysis of a randomized trial of radiation therapy of rectal cancer with/without WR-2721
97. Clinical study of radioprotective effects of amifostine (YM-08310, WR-2721) on long-term outcome for patients with cervical cancer
98. A phase I study of WR-2721 in combination with total body irradiation (TBI) in patients with refractory lymphoid malignancies
99. Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer
100. Radiochemotherapy with amifostine cytoprotection for head and neck cancer
101. Supportive use of amifostine in patients with head and neck tumors undergoing radio-chemotherapy. Is it possible to limit the duration of the application of amifostine?
102. Subcutaneous administration of amifostine during fractionated radiotherapy: A randomized phase II study
103. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer
104. Effect of amifostine on toxicities associated with sequential chemotherapy and radiation therapy for unresectable non-small-cell lung cancer: Results of a phase II trial
105. Expanded application for Ethyol (amifostine): The role of Ethyol (amifostine) as a radioprotector in lung cancer, in Radioprotection: A new option for the treatment of head and neck cancers
106. Randomized phase III study of chemoradiation±amifostine in patients with inoperable stage II-III non-small cell lung cancer (NSCLC)
107. WR-2721 and high dose cisplatin: An active combination in the treatment of metastatic melanoma
108. High dose cisplatin and WR-2721 in metastatic melanoma
109. Influence of amifostine on the pharmacokinetics of cisplatin in cancer patients
110. Pharmacokinetics of carboplatin with and without amifostine in patients with solid tumors
111. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: Results of a randomized controlled trial in patients with advanced ovarian cancer
112. Amifostine plus cisplatin plus vinorelbine in the treatment of advanced non-small cell lung cancer: A multicenter phase II study
113. Amifostine, cisplatin, and vinblastine in metastatic non-small-cell lung cancer: A report of high response rates and prolonged survival
114. Randomized phase II study of high-dose paclitaxel with or without amifostine in patients with metastatic breast cancer
115. Randomized study of a short course of weekly cisplatin with or without amifostine in advanced head and neck cancer
116. Randomized trial of carboplatin plus amifostine versus carboplatin alone in patients with advanced solid tumors
117. Carboplatin combined with amifostine, a bone marrow protectant, in the treatment of non-small-cell lung cancer: A randomised phase II study
118. A randomized trial of amifostine as a cytoprotective agent in patients receiving chemotherapy for small cell lung cancer
119. High-dose therapy with combined 5-fluorouracil and folinic acid with and without amifostine in the treatment of patients with metastatic colorectal carcinoma
120. Bone marrow protection with amifostine in the treatment of high-risk malignant lymphoma
121. Cancer vascularization: Implications in radiotherapy?
122. 'Invading edge vs. inner' (edvin) patterns of vascularisation: An interplay between angiogenic and vascular survival factors defines clinical behaviour of non small cell lung cancer
123. Prognostic and pathologic comparison of VEGF/KDR activated microvessel density (aMVD) vs. CD31 standard MVD (sMVD) in non-small cell lung cancer
124. Color doppler in differential diagnosis of breast masses
125. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: A review
126. The contribution of lactic acid to acidification of tumours: Studies of variant cells lacking lactate dehydrogenase
127. Hypofractionated and accelerated radiotherapy and cytoprotection (HypoARC). A short, safe and effective post-operative regimen for high-risk breast cancer patients
128. The relationship between extracellular lactate and tumour pH in a murine tumour model of ischaemia-reperfusion
129. Hypoxia inducible regulation of tumor associated carbonic anhydrases
130. Cytostatic activity of cisplatin in the presence of WR-2721 and its thiol metabolite WR-1065 in OVCAR-3 human ovarian cancer cells as compared to V79 fibroblasts
131. Toxicity of WR-2721 administered in single and multiple doses
132. Final report on phase I trial of WR-2721 before protracted fractionated radiation therapy
133. Phase I controlled trials of WR-2721 and cyclophosphamide
134. Protection by WR-2721 of human bone marrow function following irradiation
135. Fractionated carboplatin radiosensitization. A phase I dose escalation study
136. A phase I/II dose escalation study of docetaxel and carboplatin combination supported with amifostine and GM-CSF, in patients with incomplete response following docetaxel chemoradiotherapy. Additional chemotherapy enhances regression of residual cancer
137. Hypotensive mechanism of amifostine
138. Systemic inflammatory response syndrome associated with amifostine
139. A new administration schedule for amifostine as a radioprotector in cancer therapy
140. Topical application of WR-2721 achieves high concentrations in the rectal wall
141. Topical application of WR-2721 to prevent radiation-induced proctosigmoiditis. A phase I/II trial
142. Preliminary results of a pilot study using WR-2721 before fractionated irradiation of the head and neck to reduce salivary gland dysfunction
143. Amifostine-a radioprotector in locally advanced head and neck tumors
144. Amifostine: A radioprotector in locally advanced head and neck tumors
145. Daily amifostine given concomitantly to chemoradiation in head and neck cancer. A pilot study
146. Subcutaneous injection of Ethyol: The emerging role of Ethyol
147. Phase II evaluation of cisplatin and WR-2721 for refractory metastatic breast cancer
148. Audiological findings in a phase I protocol investigating the effect of WR 2721, high-dose cisplatin and radiation therapy in patients with locally advanced cervical carcinoma
149. Combined treatment of stage IV melanoma patients with amifostine and fotemustine - A pilot study
150. Mitomycin C and vinblastine in combination with amifostine in metastatic breast cancer. A feasibility study of the EORTC-Investigational Drug Branch for Breast Cancer (IDBBC)
151. WR-2721 protects against the hematologic toxicity of cyclophosphamide: A controlled phase II trial
152. Amifostine (WR-2721), a cytoprotective agent during high-dose cyclophosphamide treatment of non-Hodgkin's lymphomas: A phase II study
153. Amifostine can reduce mucosal damage after high-dose melphalan conditioning for peripheral blood progenitor cell autotransplant: A retrospective study
154. Pilot trial of cytoprotection with amifostine given with high-dose chemotherapy and autologous peripheral blood stem cell transplantation
155. Amifostine (WR-2721) shortens the engraftment period of 4-hydroperoxycyclophosphamide-purged bone marrow in breast cancer patients receiving high-dose chemotherapy with autologous bone marrow support
156. Salivary gland protection by amifostine in high-dose radioiodine treatment: Results of a double-blind placebo-controlled study
157. The selective cytoprotection of Ethyol (amifostine) in head and neck cancers: 18 Months follow-up data, in radioprotection: A new option for the treatment of head and neck cancers
158. Ethyol (amifostine) a new standard for head and neck cancer patients: Patients' perspectives, in radioprotection: A new option for the treatment of head and neck cancers
159. A protective effect of amifostine on dental health after radiotherapy of the head and neck
160. A randomized study of very accelerated radiotherapy with and without amifostine in head and neck squamous cell carcinoma
161. Sequential trial of concurrent hyperfractionated radiation therapy and 5-fluorouracil, cisplatin and paclitaxel with and without amifostine in patients with locally advanced head and neck squamous cell carcinoma
162. Amifostine reduces acute toxicity during radiochemotherapy in patients with localized advanced stage NSCLC
163. The use of reduced doses of amifostine to ameliorate nephrotoxicity of cisplatin/ifosfamide-based chemotherapy in patients with solid tumors
164. Amifostine and dose-intense paclitaxel in patients with advanced malignancies
165. Studies with RP-56976 (taxotere): A semi-synthetic analogue of Taxol
166. Amifostine protects normal tissues from paclitaxel toxicity while cytotoxicity against tumour cells is maintained
167. Taxol induces bcl-2 phosphorylation and death of prostate cancer cells
168. The hazards of accelerated tumor clonogene repopulation during radiotherapy
169. Biochemical modification of the toxicity and the anti-tumour effect of 5-fluorouracil and cis-platinum by WR-2721 in mice
170. Time dependence of the selective modulation of cisplatin-induced nephrotoxicity by WR-2721 in the mouse
171. Thoracic radiotherapy and daily vinorelbine as a radiosensitizer in locally advanced non small cell lung cancer: A phase I study
172. A phase I trial of amifostine (WR-2721) and melphalan in children with refractory cancer
173. Phase I study of WR-2721 and carboplatin
174. Docetaxel-induced lymphopenia in patients with solid tumors. A prospective phenotypic analysis
175. Concurrent twice-a-week docetaxel and radiotherapy. A dose escalation trial with immunological toxicity evaluation
176. Eastern Cooperative Oncology Group phase I trial of protracted venous infusion of fluorouracil plus weekly gemcitabine with concurrent radiation therapy in patients with locally advanced pancreas cancer: A regimen with unexpected early toxicity
177. Risk factors of treatment-related death in chemotherapy and thoracic radiotherapy for lung cancer
178. Combined irinotecan, docetaxel and conventionally fractionated radiotherapy in locally advanced head and neck cancer. A phase I dose escalation study
179. Results of a trial with topotecan dose escalation and concurrent thoracic radiation therapy for locally advanced, inoperable nonsmall cell lung cancer
180. Concurrent conventionally factionated radiotherapy and weekly docetaxel in the treatment of stage IIIb non-small cell lung carcinoma
181. Severe lymphocytopenia and interstitial pneumonia in patients treated with paclitaxel and simultaneous radiotherapy for non-small cell lung cancer
182. Weekly docetaxel and concomitant boost radiotherapy for non-small-cell lung cancer. A phase I/II dose escalation trial
183. Enhancement of tumor radio-response by irinotecan in human lung tumor xenografts
184. Liposomal doxorubicin and conventionally fractionated radiotherapy in the treatment of locally advanced non-small cell lung cancer and head and neck cancer
185. Enhancement of tumor radioresponse in vivo by gemcitabine
186. Radiation concurrent with gemcitabine for locally advanced head and neck cancer: A phase I trial and intracellular drug incorporation study
187. Amifostine reduces severity and incidence of Doxil-induced palmar/plantar erythrodysesthesia in rats but does not reduce Doxil antitumor efficacy or alter pharmacokinetics in mice
188. Protective effect of amifostine on Doxil/Caelyx-induced palmar-plantar erythrodysesthesia in patients with advanced cancer
189. Hypofractionation: Lessons from complications
190. Angiogenesis vs. response after combined chemo-radiotherapy of squamous cell head and neck cancer
191. Randomized multicenter trials of CHART vs. conventional radiotherapy in head-neck and non-small cell lung cancer. An interim report
192. Hypofractionated and accelerated radiotherapy with Ethyol® cytoprotection (HypoARC) for locally advanced breast cancer
193. The patterns of care outcome study for cancer of the uterine cervix. Results of the Second National Practice Survey
194. Radiation therapy alone in the treatment of carcinoma of the uterine cervix. II. Analysis of complications
195. HDR versus LDR gynecological brachytherapy revisited
196. A phase I/II study of external beam radiation, brachytherapy, and concurrent chemotherapy for patients with localized carcinoma of the esophagus (Radiation Therapy Oncology Group Study 9207): Final report
197. Long-term normal tissue effects of intraoperative electron radiation therapy (IOERT): Late sequelae, tumor recurrence, and second malignancies
198. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants
199. Differential protection of normal and malignat tissues against the cytotoxic effects of mechlorethamine
200. Modification of tumour and host response to cyclophosphamide by misonidazole and by WR2721
201. Modification by WR2721 of the response to chemotherapy of tumours and normal tissues in the mouse
202. Protective effects of S-2-(3-aminopropylamino) ethylphosphorothioic acid against radiation damage of normal tissues and fibrosarcoma in mice
203. Effect of tumor type, size and endpoint on tumor radioprotection by WR-2721
204. Protection by S-2-(3-aminopropylamino) ethylphosphorothioic acid against radiation and cyclophosphamide-induced attenuation in antitumor resistance
205. Chemopreventive doses of amifostine confer no cytoprotection in tumor nodules growing in the lungs of mice treated with cyclophosphamide
206. Cytostatic activity of cisplatin in the presence of WR2721 aminothiol metabolite WR1065 in OVCAR-3 human ovarian cancer as compared to V79 fibroblasts